Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 298

1.

Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.

Tran TA, Jennings TA, Ross JS, Nazeer T.

Am J Surg Pathol. 1998 Mar;22(3):347-54.

PMID:
9500777
[PubMed - indexed for MEDLINE]
2.

Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.

Civantos F, Marcial MA, Banks ER, Ho CK, Speights VO, Drew PA, Murphy WM, Soloway MS.

Cancer. 1995 Apr 1;75(7):1634-41.

PMID:
8826921
[PubMed - indexed for MEDLINE]
3.
4.

Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.

Unger PD, Wang Q, Gordon RE, Stock R, Stone N.

Arch Pathol Lab Med. 1997 Dec;121(12):1265-8.

PMID:
9431316
[PubMed - indexed for MEDLINE]
5.

Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.

Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD.

Urology. 2000 Aug 1;56(2):289-94.

PMID:
10925096
[PubMed - indexed for MEDLINE]
6.

[Effect of complete androgen block before radical prostatectomy for cancer of the prostate].

Gómez Veiga F, Lorenzo Patiño MJ, Díaz Bermúdez J, Duarte Novo J, Alvarez Castelo L, Chantada Abal V, Sánchez Rodríguez J, González Martín M.

Arch Esp Urol. 1997 May;50(4):355-63. Spanish.

PMID:
9313044
[PubMed - indexed for MEDLINE]
7.

Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.

Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick DG.

Urology. 1994 Jul;44(1):91-5.

PMID:
8042266
[PubMed - indexed for MEDLINE]
8.

Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.

Têtu B, Srigley JR, Boivin JC, Dupont A, Monfette G, Pinault S, Labrie F.

Am J Surg Pathol. 1991 Feb;15(2):111-20.

PMID:
1989458
[PubMed - indexed for MEDLINE]
9.

The effect of androgen deprivation on malignant and benign prostate tissue.

Guinan P, Didomenico D, Brown J, Shaw M, Sharifi R, Ray V, Shott S, Rubenstein M.

Med Oncol. 1997 Sep-Dec;14(3-4):145-52.

PMID:
9468037
[PubMed - indexed for MEDLINE]
10.

Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.

Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, Reuter VE.

Am J Surg Pathol. 1994 Oct;18(10):979-91.

PMID:
7522415
[PubMed - indexed for MEDLINE]
11.

Histopathological effects of androgen deprivation in prostatic cancer.

Civantos F, Soloway MS, Pinto JE.

Semin Urol Oncol. 1996 May;14(2 Suppl 2):22-31.

PMID:
8725888
[PubMed - indexed for MEDLINE]
12.

Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.

Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K.

Cancer. 1999 Apr 15;85(8):1822-7.

PMID:
10223578
[PubMed - indexed for MEDLINE]
13.

Pathologic changes associated with androgen deprivation therapy for prostate cancer.

Murphy WM, Soloway MS, Barrows GH.

Cancer. 1991 Aug 15;68(4):821-8.

PMID:
1906775
[PubMed - indexed for MEDLINE]
14.

[The effect of combined endocrine therapy on prostate and testis].

Kong X, Zeng L, Xia T, Wang J, Mi P, Na Y, Xue Z, Pan B, Hao J, Gu F, Guo Y.

Zhonghua Wai Ke Za Zhi. 1999 Apr;37(4):231-4. Chinese.

PMID:
11829828
[PubMed - indexed for MEDLINE]
15.

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.

Vailancourt L, Ttu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F.

Am J Surg Pathol. 1996 Jan;20(1):86-93.

PMID:
8540613
[PubMed - indexed for MEDLINE]
16.

Effects of androgen deprivation prior to radical prostatectomy in 375 patients.

Tunn UW, Acar O, Goldschmidt AJ.

Urol Int. 1996;56 Suppl 1:6-12.

PMID:
8776811
[PubMed - indexed for MEDLINE]
17.

Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process.

Egan AJ, Lopez-Beltran A, Bostwick DG.

Am J Surg Pathol. 1997 Aug;21(8):931-5.

PMID:
9255256
[PubMed - indexed for MEDLINE]
18.
19.

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.

PMID:
15050332
[PubMed - indexed for MEDLINE]
20.

Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate.

Hara I, Miyake H, Yamada Y, Takechi Y, Hara S, Gotoh A, Fujisawa M, Okada H, Arakawa S, Soejima T, Sugimura K, Kamidono S.

Int J Urol. 2002 Jun;9(6):322-8; discussion 328.

PMID:
12269247
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk